Back to Search Start Over

Combining Flow and Mass Cytometry in the Search for Biomarkers in Chronic Graft-versus-Host Disease

Authors :
Stikvoort, Arwen
Chen, Yang
Radestad, Emelie
Torlen, Johan
Lakshmikanth, Tadepally
Bjorklund, Andreas
Mikes, Jaromir
Achour, Adnane
Gertow, Jens
Sundberg, Berit
Remberger, Mats
Sundin, Mikael
Mattsson, Jonas
Brodin, Petter
Uhlin, Michael
Stikvoort, Arwen
Chen, Yang
Radestad, Emelie
Torlen, Johan
Lakshmikanth, Tadepally
Bjorklund, Andreas
Mikes, Jaromir
Achour, Adnane
Gertow, Jens
Sundberg, Berit
Remberger, Mats
Sundin, Mikael
Mattsson, Jonas
Brodin, Petter
Uhlin, Michael
Publication Year :
2017

Abstract

Chronic graft-versus-host disease (cGVHD) is a debilitating complication arising in around half of all patients treated with an allogeneic hematopoietic stem cell transplantation. Even though treatment of severe cGVHD has improved during recent years, it remains one of the main causes of morbidity and mortality in affected patients. Biomarkers in blood that could aid in the diagnosis and classification of cGVHD severity are needed for the development of novel treatment strategies that can alleviate symptoms and reduce the need for painful and sometimes complicated tissue biopsies. Methods that comprehensively profile complex biological systems such as the immune system can reveal unanticipated markers when used with the appropriate methods of data analysis. Here, we used mass cytometry, flow cytometry, enzyme-linked immunosorbent assay, and multiplex assays to systematically profile immune cell populations in 68 patients with varying grades of cGVHD. We identified multiple subpopulations across T, B, and NK-cell lineages that distinguished patients with cGVHD from those without cGVHD and which were associated in varying ways with severity of cGVHD. Specifically, initial flow cytometry demonstrated that patients with more severe cGVHD had lower mucosal-associated T cell frequencies, with a concomitant higher level of CD38 expression on T cells. Mass cytometry could identify unique subpopulations specific for cGVHD severity albeit with some seemingly conflicting results. For instance, patients with severe cGVHD had an increased frequency of activated B cells compared to patients with moderate cGVHD while activated B cells were found at a reduced frequency in patients with mild cGVHD compared to patients without cGVHD. Moreover, results indicate it may be possible to validate mass cytometry results with clinically viable, smaller flow cytometry panels. Finally, no differences in levels of blood soluble markers could be identified, with the exception for the semi-solubl<br />QC 20170705

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1235072532
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.3389.fimmu.2017.00717